ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an
end-to-end commercial biopharmaceutical company dedicated to
manufacturing, marketing and developing specialty plasma-derived
biologics, today announced that it intends to offer shares of its
common stock for sale in an underwritten public offering. The
Company intends to grant the underwriters of the offering a 30-day
option to purchase up to an additional 15 percent of the number of
shares of common stock sold in connection with the offering. The
proposed offering is subject to market and other conditions, and
there can be no assurance as to whether or when the offering may be
completed, or as to the actual size or terms of the
offering.
ADMA intends to use the net proceeds from this
offering (i) to advance the commercial sales of its U.S. Food and
Drug Administration (FDA)-approved products through the procurement
of raw materials for the manufacturing of BIVIGAM® and ASCENIV™;
(ii) to expand its plasma collection facility network; (iii) to
scale up the manufacturing capacity of its Boca Raton facility and
to make continuous improvements in order to adhere to current Good
Manufacturing Practice (cGMP) compliance; (iv) to explore business
development opportunities; and (v) for general corporate purposes
and other capital expenditures.
Raymond James & Associates, Inc. and Cantor
Fitzgerald & Co. are acting as joint book-running managers of
the proposed offering.
The securities described above are being offered
by the Company pursuant to a “shelf” registration statement on Form
S-3 (File No. 333-256643) previously filed with the Securities and
Exchange Commission (“SEC”) and declared effective by the SEC on
August 3, 2021. The preliminary prospectus supplement and the
accompanying prospectus relating to the offering will be filed with
the SEC and will be available on the SEC’s website at www.sec.gov.
Electronic copies of the preliminary prospectus supplement and the
accompanying prospectus relating to the offering may be obtained,
when available, from Raymond James & Associates, Inc.,
Attention: Equity Syndicate, 880 Carillon Parkway, St. Petersburg,
Florida 33716, or by telephone at (800) 248-8863, or e-mail at
prospectus@raymondjames.com, or from Cantor Fitzgerald & Co.,
Attn: Capital Markets, 499 Park Avenue, 4th Floor, New York, New
York 10022 or by email at prospectus@cantor.com.
Before investing in the offering, you should
read in their entirety the preliminary prospectus supplement and
its accompanying prospectus to be filed with the SEC, and the other
documents that the Company has filed with the SEC that will be
incorporated by reference in the prospectus supplement and its
accompanying prospectus, which will provide more information about
the Company and the offering.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy any securities
described herein, nor shall there be any sale of these securities
in any state or jurisdiction in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under
the securities laws of any such state or jurisdiction.
About ADMA Biologics, Inc.
(ADMA)
ADMA Biologics is an end-to-end commercial
biopharmaceutical company dedicated to manufacturing, marketing and
developing specialty plasma-derived biologics for the treatment of
immunodeficient patients at risk for infection and others at risk
for certain infectious diseases. ADMA currently manufactures and
markets three United States Food and Drug Administration
(FDA)-approved plasma-derived biologics for the treatment of immune
deficiencies and the prevention of certain infectious diseases:
ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for
the treatment of primary humoral immunodeficiency (PI); BIVIGAM®
(immune globulin intravenous, human) for the treatment of PI; and
NABI-HB® (hepatitis B immune globulin, human) to provide enhanced
immunity against the hepatitis B virus. ADMA manufactures its
immune globulin products at its FDA-licensed plasma fractionation
and purification facility located in Boca Raton, Florida. Through
its ADMA BioCenters subsidiary, ADMA also operates as an
FDA-approved source plasma collector in the U.S., which provides a
portion of its blood plasma for the manufacture of its products.
ADMA’s mission is to manufacture, market and develop specialty
plasma-derived, human immune globulins targeted to niche patient
populations for the treatment and prevention of certain infectious
diseases and management of immune compromised patient populations
who suffer from an underlying immune deficiency, or who may be
immune compromised for other medical reasons. ADMA has received
U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and
10,259,865 related to certain aspects of its products and product
candidates. For more information, please visit
www.admabiologics.com.
Cautionary Note Regarding
Forward-Looking Statements
This press release contains “forward-looking
statements” pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995, about ADMA Biologics,
Inc. (“we,” “our” or the “Company”). Forward-looking statements
include, without limitation, any statement that may predict,
forecast, indicate, or imply future results, performance or
achievements, and may contain such words as “estimate,” “project,”
“intend,” “forecast,” “target,” “anticipate,” “plan,” “planning,”
“expect,” “believe,” “will,” “is likely,” “will likely,” “should,”
“could,” “would,” “may,” or, in each case, their negative, or words
or expressions of similar meaning. These forward-looking statements
include statements about the offering, ADMA’s intention to grant
the underwriters a 30-day option to purchase additional shares in
the offering, and ADMA’s intended use of proceeds generated from
the offering. Actual events or results may differ materially from
those described in this document due to a number of important
factors. Current and prospective security holders are cautioned
that there also can be no assurance that the forward-looking
statements included in this press release will prove to be
accurate. Except to the extent required by applicable laws or
rules, ADMA does not undertake any obligation to update any
forward-looking statements or to announce revisions to any of the
forward-looking statements. Forward-looking statements are subject
to many risks, uncertainties and other factors that could cause our
actual results, and the timing of certain events, to differ
materially from any future results expressed or implied by the
forward-looking statements, including, but not limited to, risks
and uncertainties related to market conditions and satisfaction of
customary closing conditions related to the public offering and the
risks and uncertainties described in our filings with the U.S.
Securities and Exchange Commission, including our most recent
reports on Form 10-K, 10-Q and 8-K, and any amendments thereto.
COMPANY CONTACT:
Skyler BloomDirector, Investor Relations and
Corporate Strategy | 201-478-5552 | sbloom@admabio.com
INVESTOR RELATIONS
CONTACT:Michelle Pappanastos Senior Managing Director,
Argot Partners | 212-600-1902 |
michelle@argotpartners.com
Adma Biologics (NASDAQ:ADMA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Adma Biologics (NASDAQ:ADMA)
Historical Stock Chart
From Sep 2023 to Sep 2024